Previous studies have shown that Oct4 and Nanog can enhance both tumor-initiating capability and the EMT, and the expression of either Oct4 or Nanog has been correlated with a poor outcome for patients with lung adenocarcinoma 32. This evidence concerns the gene POU5F1 and neoplasm.